Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Summary

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Timeline

Start

2024-12-12

Primary completion

2027-06

Completion

2027-06

Drugs

Indications